## Mirtazapine is a noradrenergic and specific serotonergic antidepressant (NaSSA) with a novel mode of action that differs from other antidepressants that are currently available. Clinical trials have demonstrated it to have good antidepressant efficacy and excellent tolerability. Analysis of the r
An overview of the clinical efficacy of mirtazapine
β Scribed by O. Benkert; M. Muller; A. Szegedi
- Publisher
- John Wiley and Sons
- Year
- 2002
- Tongue
- English
- Weight
- 63 KB
- Volume
- 17
- Category
- Article
- ISSN
- 0885-6222
- DOI
- 10.1002/hup.397
No coin nor oath required. For personal study only.
β¦ Synopsis
Mirtazapine is at least as effective as the tricyclic antidepressants and trazodone in a wide range of patient subgroups including in- and out-patients with moderate to severe depression. It also appears to be at least as effective as the serotonin and noradrenaline reuptake inhibitor venlafaxine in the treatment of severely depressed melancholic patients. When compared with the selective serotonin reuptake inhibitors (SSRIs), mirtazapine shows a significantly earlier onset of action. Further analysis of a study comparing mirtazapine with the SSRI paroxetine indicated that early improvement was a highly sensitive predictor of later stable response for both drugs. The positive predictive value of an early improvement was significantly higher during mirtazapine treatment compared with paroxetine. The negative predictive value approached maximum values as early as week 2 with mirtazapine and week 3 with paroxetine. This suggests that the predictability of the response to treatment is better with mirtazapine than with paroxetine.
π SIMILAR VOLUMES
The term synucleinopathies is used to name a group of neurodegenerative disorders characterized by fibrillary aggregates of β£-synuclein protein in the cytoplasm of selective populations of neurons and glia. These disorders include Parkinson's disease (PD), dementia with Lewy bodies (DLB), pure auton
I existing clinical trials or attempt to highlight the exciting new developments emerging from the laboratories of our basic scientists and today's clinical trials. Likewise I do not decry the still daunting problems which face those concerned with the common, therapy-resistant cancers which kill so